tbuckley/cabot-search huggingface dataset:
Macrophages come to mind as keys to cognitive decline
Authors: D.G. Harrison, Tomasz J. Guzik
Journal: Journal of Clinical Investigation (2016)

Cognitive impairment, an underappreciated consequence of hypertension, is linked to cerebral arteriolar disease through poorly defined mechanisms. A study by Faraco et al. in this issue of the JCI points to perturbations of neurovascular unit coupling caused by perivascular macrophages (PVMs) as a cause of hypertension-related cognitive impairment. Angiotensin II (Ang II) was shown to activate PVMs, causing them to produce superoxide and thereby alter the proper functioning of the adjacent arterioles. Faraco and colleagues also show that disruption of the blood-brain barrier occurs in hypertension, allowing circulating Ang II to access PVMs. This study provides important new insight into the role of inflammatory cells in the genesis of vascular dementia.
A Role for α-Actinin in Inside-out αIIbβ3 Signaling.
Authors: Seiji Tadokoro, Masamichi Shiraga, Hirokazu Kashiwagi, Tsuyoshi Kamae, Masao Akiyama, Tsuyoshi Nakazawa, Yuzuru Kanakura, Yoshiaki Tomiyama
Journal: Blood (2008)
A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).
Authors: Nancy L. Bartlett, John G. Gribben, Ralph V. Boccia, Michael S. Milder, David M. Aboulafia, Januario Castro, Ian Flinn, Brandon Hayes-Lattin, Lawrence Kaplan, Thomas Lin, Jennifer B. Lucas, David G. Maloney, Peter McLaughlin, Peter A. McSweeney, Ann Mohrbacher, Charles Redfern, Ronald Steis, Joe J. Stephenson, Roger Strair, Ronald J. Berenson, Mark W. Frohlich
Journal: Blood (2004)
MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute Lymphocytic Leukemia (ALL) Cells.
Authors: Christopher Hickey, Sebastian Schwind, Heiko Becker, Houda Alachkar, Ramiro Garzon, Yue-Zhong Wu, Shujun Liu, Danilo Perrotti, Guido Marcucci
Journal: Blood (2009)
Myelodysplastic Syndromes with Myelofibrosis May Be a Target for the JAK2 V617F Tyrosine Kinase Mutation.
Authors: Kazuma Ohyashiki, Yasuo Aota, Akihiko Gotoh, Keisuke Miyazawa, Yukihiko Kimura, Junko H. Ohyashiki
Journal: Blood (2005)
The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity
Authors: Michal Wieczorek, Joseph Tcherkezian, Cynthia Bernier, Andrea E. Prota, Sami Chaaban, Yannève Rolland, Claude Godbout, Mark A. Hancock, Joseph C. Arezzo, Ozhan Ocal, Cecilia Rocha, Natacha Olieric, Anita Hall, Hui Ding, Alexandre Bramoullé, Matthew G. Annis, George Zogopoulos, Patrick G. Harran, Thomas M. Wilkie, Rolf A. Brekken, Peter M. Siegel, Michel O. Steinmetz, Gordon C. Shore, Gary J. Brouhard, Anne Roulston
Journal: Science Translational Medicine (2016)

A compound that binds to tubulin in an unusual way has superior antitumor efficacy and safety and has a distinctive impact on microtubule curvature and dynamics.
Preventive Effects of Cardotoxicities By Liposomal Anthracyclines non Pegilated in 95 Perspective Patients Affected By Lymphoma and Monitored By Biomarkers and Ecocardiography
Authors: Guido Gini, Jacopo Olivieri, Caterina Bocci, Michela Sampaolo, Silvia Trappolini, Attilio Olivieri, Massimo Offidani, Serena Rupoli, Antonella Poloni, Anna Rita Scortechini, Debora Capelli, Mauro Montanari, Ilaria Scortechini, Gian Piero Perna, Pietro Leoni
Journal: Blood (2014)
SAT0151 Imaging and Histopathological Changes To Tocilizumab in Patients with Moderate To Severe Ra: A Single Centre Randomized Double-Blind Placebo-Controlled Study
Authors: A.S. Zayat, C. Wong, R. Cuthbert, Z. Ash, S.J. Bingham, P. Emery, M.H. Buch
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Tocilizumab (TCZ) is a well-established biologic therapy in the treatment of rheumatoid arthritis (RA). There is limited data on imaging and synovial tissue histology changes. <h3>Objectives</h3> To evaluate level of response as defined by power Doppler (PD) ultrasound (US) and synovial tissue histology changes. <h3>Methods</h3> Patients with RA, inefficacy to minimum one DMARD +/− TNFi, with DAS28≥3.2 and knee synovitis amenable to synovial biopsy were recruited to this open-label 48-week study. Patients randomised to TCZ/methotrexate (MTX) for 48 weeks or placebo (PBO)/MTX for the first 16 weeks followed by TCZ/MTX until week 48. Clinical and US hand, wrist and knee assessments with US-guided knee synovial biopsy at baseline (BL), weeks 12 and 48 (biopsy optional). US was scored accrording to OMERACT 0–3 grey scale and PD synovitis scoring system. Synovial tissue was assessed for synovial inflammatory infiltrate, stromal cell density, synovial lining on 0–3 scale and overall synovitis (0–9 scale) determined. <h3>Results</h3> 15 patients recruited: 12 (80%) females; 9 received TCZ/MTX, 6 PBO/MTX. 2 patients withdrew at each arm, one due to TCZ infusion reaction. Week 16: 33% (3/9) TCZ/MTX achieved DAS28ESR-rem vs 0 PBO+MTX, latter remaining in moderate/high disease activity. Week 48: 92% (12/13) whole group in DAS28ESR-rem. US response: 38% (3/8) TCZ/MTX group who had BL PD synovitis in hand/wrist had absence of PD synovitis at week 16 vs none PBO/MTX group. All patients with abnormal BL PD in knees (median (IQR) PD score of 2 (0–9)) had improved week 48 PD score (median (IQR) PD score of 0 (0–1)). 13 patients (8 TCZ/MTX, 5 PBO/MTX) had synovial biopsies obtained weeks 0 &amp; 12; 21/26 samples (80%) samples useable. No difference between pre- and week 12 synovitis score in both groups. Median (IQR) total synovitis score at BL and after week 12 respectively of 3 (2.75, 4.25) and 3 (2.5–4) in the TCZ/MTX group vs 6 (4,7) and 6 (4,6) in PBO/MTX group. BL total synovitis score did not predict early or late response. <h3>Conclusions</h3> TCZ/MTX was associated with significant clinical and imaging improvement compared to MTX alone. An absence of change in synovial infiltrate with TCZ/MTX at 12 weeks suggests a different mechanism for response compared to other anti-cytokine therapies such as the TNFi. Further histochemistry analysis and investigation may potentially determine mechanism and indicators of response on a tissue level. <h3>Disclosure of Interest</h3> None declared
ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia
Authors: Maria J. Monte, Marta Alonso-Peña, Oscar Briz, Elisa Herraez, Carmen Berasain, Josepmaria Argemi, Jesus Prieto, Jose J.G. Marin
Journal: Journal of Hepatology (2016)
PTH-022 A Novel Experience of The Pillcam® ESO 3 Capsule Endoscope In Patients Unwilling To Undergo Conventional Upper GI Endoscopy
Authors: H-L Ching, V Phillips, A Healy, R Sidhu, ME McAlindon
Journal: Gut (2016)

<h3>Introduction</h3> Gastroscopy (OGD) is the gold standard test for investigating dyspepsia, but is uncomfortable, incurs the risk of intubation and sedation and has a diagnostic yield in our practice in 16.4% (data submitted). Capsule endoscopy is safe, non-invasive and well-tolerated. Furthermore, capsules to image the oesophagus are now used in routine clinical practice. We test the feasibility and safety of a novel protocol using the ESO3 upper gastrointestinal (GI) capsule (Given Imaging Ltd) which boasts an improved field of view and battery life compared to earlier models. <h3>Methods</h3> All consecutive patients undergoing investigation with the ESO3, between December 2015 and February 2016, were prospectively recruited. All patients required upper GI investigation but had declined conventional OGD ± barium studies. Patients were asked to drink 1 L of water containing simethicone prior to the procedure. They were then asked to swallow the ESO3 and adopt lying positions in 3 different directions at 3 angles (30° head down/up and horizontal) for 3 minutes each. Data on patient demographics, procedural data and patient tolerance was reviewed. <h3>Results</h3> 10 patients (mean age 49±17.3 years, 50% male) were included. Indications for the ESO3 included investigation for dyspepsia (n = 2), iron deficiency anaemia (n = 2), variceal screening (n = 3), suspected gastric Crohn’s disease (n = 1), subjective dysphagia (n = 1) and assessment of oesophageal ulcer healing (n = 1). Pathologies detected at CE included oesophagitis (n = 2), hiatus hernias (n = 3), oesophageal ulcers and erosions (n = 3), oesophageal varices (n = 3) and gastric and Cameron ulcers (n = 1, each). The mean time of the ESO3 transit in the oesophagus, stomach and small bowel was 12±9 secs, 58±27 mins, 23±22 mins respectively. The mean reading time for the capsule video was faster with the accelerated reading mode (39±18.4 mins) than with standard mode (79±14.6 mins) using the RAPID® software (p &lt; 0.05). Mean post-procedural anxiety, discomfort and pain scores were excellent (scores from worst-best =0-10; 0, 0.7, 0 respectively). Visualisation (grade from worst-best =1-5) of all areas of the upper GI tract was also excellent; oesophagus (5±0), gastric cardia (5±03), fundus (4±1.1), body (5±0.6), antrum (5±0.3) and the first and second part of the duodenum (both 5±0). Complete examination to D2 was achieved in 80%. No complications were seen. <h3>Conclusion</h3> We report the first study of a novel protocol demonstrating the feasibility and safety of the ESO3. Further protocol amendments are necessary to improve reading time and visualisation while randomised control trials are needed to compare diagnostic yield to conventional OGD. However, the excellent patient tolerance affords an alternative upper GI investigative tool worth pursuing. <h3>Disclosure of Interest</h3> None Declared
FRI0553 Obesity and The Risk of Systemic Lupus Erythematosus in The Nurses' Health Studies:
Authors: S.K. Tedeschi, M. Barbhaiya, B. Lu, S. Malspeis, J.A. Sparks, E.W. Karlson, K.H. Costenbader
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Obesity in the U.S. has increased to an alarming extent over the past four decades. Obesity is related to risk of several autoimmune diseases, possibly via generation of adipokines and inflammatory cytokines. Prospective studies of obesity and systemic lupus erythematosus (SLE) risk are lacking however. <h3>Objectives</h3> To prospectively evaluate the association between obesity and SLE risk <h3>Methods</h3> We conducted a prospective cohort study of women in the U.S. Nurses9 Health Studies (NHS, 1976–2012, age 30–55 at baseline; NHSII, 1989–2013, age 25–42 at baseline). Incident SLE was confirmed by American College of Rheumatology 1997 criteria. Body mass index (BMI, kg/m<sup>2</sup>) was reported at baseline and on biennial questionnaires. Cumulative average BMI (18.5 to &lt;25 [normal (ref)], 25 to &lt;30 [overweight], ≥30 [obese]) was the primary exposure. Cox proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for SLE by cumulative average BMI category, adjusting for covariates (Table). Analyses were conducted in each cohort; results were meta-analyzed with a DerSimonian-Laird random effects model. Sensitivity analyses: 1) excluded women with cancer, and 2) started in 1988 (NHS)/1989 (NHSII) when obesity prevalence in the U.S. was most steeply increasing. <h3>Results</h3> We identified 154 SLE cases in NHS and 113 cases in NHSII. At baseline, obesity was present in 8.4% (NHS) and 11.8% (NHSII); mean age was 42.7 (SD 7.1) years (NHS) and 34.4 (SD 4.6) years (NHSII); 92% were White in each cohort. Obesity was significantly associated with SLE risk among women in NHSII, but not NHS (Table). In NHSII, a strong dose-dependent relationship between BMI and SLE risk was observed. After meta-analysis, obese women had a non-significantly elevated SLE risk compared to normal weight women (p trend 0.02). Results were similar in sensitivity analyses excluding women with cancer (HR 1.48, 95%CI 0.93–2.37, p trend 0.03). In analyses starting in 1988/1989, obese women had an increased SLE risk (meta-analyzed HR 1.76, 95%CI 1.19–2.58) compared to normal weight women (p trend &lt;0.01). <h3>Conclusions</h3> Obesity was associated with a significant 88% increase in SLE risk in the younger cohort, NHSII, but did not significantly elevate SLE risk in NHS subjects. Meta-analysis revealed a non-significant 49% increased risk of SLE in obese women. We observed a stronger obesity-associated SLE risk when analyses started in 1988/1989 in both cohorts. The discrepant results between the cohorts are not fully understood and deserve further study. <h3>Disclosure of Interest</h3> None declared
SAT0199 Nmr-Based Metabolomic Analysis for The Diagnosis of Systemic Sclerosis
Authors: K.H. Jung, S. Oh, W. Park, M.J. Lim, S. Kwon, S. Park
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic sclerosis (SSc) is a complex multi-organ autoimmune disease that is caused by inflammation, vasculopathy and fibrosis. Clinical heterogeneity, unpredictable course, high mortality and resistance to treatment make physicians still frustrated. Recently, there are unmet needs of useful biomarkers for diagnosis, disease activity and severity of SSc. Metabolomics is expected to be a useful tool for the identification of biomarkers and new therapeutic targets. Several researchers have applied metabolomics to autoimmune diseases such as systemic lupus erythematosus, and rheumatoid arthritis. <h3>Objectives</h3> To identify the biomarker candidates for the diagnosis of SSc using metabolomic analysis. <h3>Methods</h3> Fifty-five patients (48 females (87%); mean age 59.30 ± 11.44 years; disease duration 6.92 ± 4.36 years; 11 diffuse cutaneous SSc, 44 limited cutaneous SSc) and thirty age, gender matched healthy controls (HCs) were enrolled. Serum samples after 8 h of fasting were stored at -80° and analysed using nuclear magnetic resonance (NMR)-based metabolomics. <h3>Results</h3> Multivariate analysis showed metabolic differences between SSc and HCs using partial least squares discrimination analysis (PLS-DA: R<sup>2</sup>Y=0.654, Q<sup>2</sup>=0.482) and orthogonal partial least squares discrimination analysis (OPLS-DA: R<sup>2</sup>Y=0.83, Q<sup>2</sup>=0.674) (Figure 1). We identified nine discriminatory metabolites (<i>p</i>&lt;0.05): isopropanol, lactate, 2-oxoisocaproate, glucose, and formate were increased and pyruvate, glutamate, methylguanidine, and methanol were decreased in SSc compared with those in the HCs. Using these metabolites for diagnosis of SSc, sensitivity was 96.36% and specificity was 80% by Leave-one-out analysis. <h3>Conclusions</h3> There are considerable differences in the serum metabolomic characteristics between SSc and HCs. We expect that metabolomic analysis can be a useful tool for identification of potential diagnostic biomarkers of SSc. <h3>Disclosure of Interest</h3> None declared
Seven day service policy lacked transparency, review concludes
Authors: Gareth Iacobucci
Journal: BMJ (2016)

The UK government must do more to “show its workings” when presenting the case for new policies such as seven day services in the NHS, says a major new review of government transparency.

The review, the first assessment of transparency across UK government, identified wide variation across and within departments that made it difficult for the public and researchers to scrutinise policy proposals.1

The charity Sense about Science, which produced the report with the Institute for Government and the Alliance for Useful Evidence, said that government departments seem often to have assembled an …
High C-Terminal Cross-Linking Telopeptide of Collagen Type-I (CTX) Predicts for Poor Overall Survival in Patients with Multiple Myeloma Who Receive Frontline Therapy with Immunomodulatory Drugs (IMiDs) but Not with Bortezomib-Based Regimens
Authors: Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Athanasios Papatheodorou, Nikolaos Kanellias, Magdalini Migkou, Maria Gavriatopoulou, Maria Gkotzamanidou, Evangelos Eleutherakis-Papaiakovou, Lia A Moulopoulos, Meletios A Dimopoulos
Journal: Blood (2012)
AB0223 Neopterin in Early Arthritis: Disease Activity and Serum Markers of Inflammation, Correlation into Three Time Periods, An Experience in Argentina
Authors: M.Y. Aguirre, D. Pereira, C. Pena, M. Garcia
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Neopterin is a molecule produced by monocytes by stimulation of Interferon Gamma. It is elevated in infections, autoimmune diseases, malignancies, transplant rejection, neurodegenerative, and cardiovascular conditions such as pregnancy [1,2]. <h3>Objectives</h3> To investigate the serum levels of neopterin in patients with early arthritis (EA) and establish its relationship with activity disease. <h3>Methods</h3> Non-experimental, prospective and longitudinal study was conducted in patients with EA (&lt;2 years of evolution) and &gt;18 years of age. On days 0, 6 and 12 months physical examination and analysis of parameters of activity within 7 days of the blood sample (DAS28, HAQ, EVA and ESR, CRP, FR, anti-CCP and ANA) were performed. Neopterin determination was made by ELISA reagent kit Gen Way Biotech Inc and calculated with Logit-log. Normal value below 10 nmol/l was considered. Radiographs of hands and feet at the initial visit and 12 months through SENS method (score of grips and erosions) were evaluated. Neopterin values were compared to a control population of 47 healthy individuals. Stata 9.0 for data analysis. Fisher 2 to chi-2. <h3>Results</h3> Twenty-seven patients (36±13 years), 19 (70%) women and 8 (30%) males were evaluated. At first the mean value of neopterin in EA Group was 7.51 (5.5–11.4) vs 5.32 (3.5–6.44) in the control grou p (p=0.0004). It was correlated with scores of activity, and the activity measured by DAS28 was observed that in the initial period: Neopterin &gt;10 nmol/L (n=8): 3.37 [2.53–4.36] vs Neopterin standard value (n=19): 3.86 [3.24 -4.54] (p=0.34).At 6 months: Neopterin&gt;10 (n=5): 3.33 [2.14–4.33] vs Neopterin standard (n=22): 2.96 [2.66–3.73] (p=0.6); and at 12 months: Neopterin &gt;10 (n=9): 3.08 [2.49–3.79] vs Neopterin standard (n=18): 2.90 [2.34–3.27] p=0.53. No correlation was found between neopterin and DAS 28. <h3>Conclusions</h3> In this study the results showed no correlation between disease activity (DAS28) and high concentrations of serological marker (neopterin) compared in the three periods or with other international assessment rates. Correlation was observed between DAS 28 and acute phase reactants (ERS and CRP) in the three periods. It would require studies with more patients to confirm these data. <h3>References</h3> Machold KP, Smolen JS. J Rheumatol. 2002; 29: 2278- 2287. Neopterin as a Marker for Immune System Activation. Current Drug Metabolism, 2002, 3, 175–187. Noninvasive monitoring using serum amyloid A and serum neopterin in cardiac transplantation. Clin. Chim. Acta 1998; 276:63–74. <h3>Disclosure of Interest</h3> None declared
siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model
Authors: João Miguel Freire, Inês Rego de Figueiredo, Javier Valle, Ana Salomé Veiga, David Andreu, Francisco J. Enguita, Miguel A.R.B. Castanho
Journal: Journal of Controlled Release (2016)
NIMG-68<sup>11</sup>C-METHIONIN-PET ENABLES EARLY DETECTION AND SUBSEQUENT INTERVENTION OF RECURRENCE IN 1p/19q CO-DELETED GLIOMAS
Authors: Keisuke Ueki, Fumi Higuchi, Ryohei Ohtani, Takeshi Udzuka, Setsu Sakamoto, Phyo Kim
Journal: Neuro-Oncology (2015)

1p/19q co-deleted gliomas show good response to genotoxic treatment and majority of patients are expected to live more than 14 years. In addition, radiation therapy is frequently deferred to avoid potential cognitive function disturbance. In such cases, monitoring recurrence and hence decision to re-intervene is sometimes difficult. We have been using 11C-methionine -PET (MET-PET) to this purpose. After initial intervention, 32 patients were followed with MRI (every 4 months) and MET-PET (every 12 months and when MRI suggestive). Of those, regrowth was detected in 18 cases (mPFS 75 months). The recurrent lesion was localized and surgically removable in 15 cases, and none of the recurrent lesion was WHO grade 4. Treatment after recurrence depended on the previous treatment, but the majority (10/15) underwent chemo/radiation therapy with TMZ because the initial adjuvant therapy was with PCV therapy. Only 2 patients died in the median follow-up time of 76 months. MET-PET appears to be an useful method to confirm recurrence in 1p/19q co-deleted gliomas, allowing earlier intervention.
Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
Authors: Jesús F. San-Miguel, Vania T.M. Hungria, Sung-Soo Yoon, Meral Beksac, Meletios A. Dimopoulos, Ashraf Elghandour, Wieslaw W. Jedrzejczak, Andreas Guenther, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Robert L. Schlossman, Jian Hou, Philippe Moreau, Sagar Lonial, Jae Hoon Lee, Hermann Einsele, Monika Sopala, Bourras-Rezki Bengoudifa, Claudia Corrado, Paul G. Richardson
Journal: Blood (2015)
Persistence of Recipient-Derived Antiviral T cells Severely Influence Donor Chimerism Post Allogeneic HSCT,
Authors: Sylvia Borchers, Michael Stadler, Susanne Luther, Tina Ganzenmueller, Brigitte Pabst, Stefanie Buchholz, Elke Dammann, Arnold Ganser, Eva M Weissinger
Journal: Blood (2011)
AB0570 Igg4 Related Disease: Protean Clinical Manifestations and A Diagnostic Conundrum
Authors: S. Chittalae, V. Singh, P. Efthimiou
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> - Immunoglobulin G4-related disease (IgG4-RD) is a multisystemic fibro-inflammatory condition characterized by tumefactive lesions, dense lymphoplasmacytic infiltrate, storiform fibrosis and obliterative phlebitis. Serum IgG4 levels are usually elevated in 70–90% of cases. The mean age at diagnosis is 60 years with a striking male preponderance. (Male:Female – 8:3) <h3>Objectives</h3> To present a single center experience with IgG4-RD and the diagnostic and therapeutic challenges encountered. <h3>Methods</h3> A retrospective case review at an urban teaching hospital was done over a year after the availability of quantitative assessment of IgG4 levels and tissue immuno-histological staining techniques. This revealed four cases of IgG4-RD involving the pancreas, retroperitoneum, kidney and meninges demonstrating its multi-systemic nature. <h3>Results</h3> We encountered a M:F ratio of 3:1 with mean age at presentation being 66 year Case 1: A 76-year-old male with significant weight loss, erroneously diagnosed with pancreatic tail malignancy, underwent distal pancreatectomy and was subsequently diagnosed with AIP on biopsy. Case 2: A 71-year-old male s/p left partial nephrectomy 4 years ago with an incidental finding of right kidney mass (2x2x2cm). After undergoing right partial nephrectomy, he was diagnosed with IgG4-related kidney disease. Case 3: A 56-year-old male with abdominal pain and worsening renal function had MRI findings of a heterogeneous retroperitoneal mass attached to the right kidney. Biopsy revealed a diagnosis of IgG4-retroperitoneal fibrosis. Case 4: A 57-year-old female presented with headache, bilateral lower extremity weakness and gait abnormality. Elevated serum IgG4, leptomeningeal enhancement on MRI and dural biopsy all suggested IgG4-related pacchymeningitis. <h3>Conclusions</h3> IgG4-RD often presents as a diagnostic conundrum. There is a need to increase clinician awareness of IgG4-RD, since early identification and subsequent treatment with immunomodulators may prevent disease progression and prevent complications and/or unnecessary surgeries. PET/CT may prove to be a useful adjunctive imaging technique to investigate for multi-system involvement. Over reliance on serum IgG4 levels for screening may result in missed diagnosis in a significant percentage of patients. <h3>Disclosure of Interest</h3> None declared
Annexin A2 Deficient Mice Are Resistant to Pathogenic Effects of Antiphospholipid Antibodies in Vivo
Authors: Zurina Romay-Penabad, Guadalupe Montiel-Manzano, Elizabeth Pappalardo, Katherine A. Hajjar, Tuya Shilagard, Gracie Vargas, Silvia S Pierangeli
Journal: Blood (2008)